It is therefore appealing to speculate that an increase in cellular plasticity could underlie limited response to mTOR inhibitors in HNSCC, and it underscores the need to therapeutically target multiple deregulated translation hubs that include phospho-eIF2 to curtail the development of intrinsically resistant tumor cells. This evidence concerns the gene MTOR and neoplasm.